Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
IKNA

IKNA - Ikena Oncology, Inc. Stock Price, Fair Value and News

1.66USD-0.04 (-2.35%)Market Closed

Market Summary

IKNA
USD1.66-0.04
Market Closed
-2.35%

IKNA Stock Price

View Fullscreen

IKNA RSI Chart

IKNA Valuation

Market Cap

80.1M

Price/Earnings (Trailing)

-1.14

Price/Sales (Trailing)

8.74

EV/EBITDA

-0.4

Price/Free Cashflow

-1.02

IKNA Price/Sales (Trailing)

IKNA Profitability

EBT Margin

-745.90%

Return on Equity

-45.12%

Return on Assets

-40.57%

Free Cashflow Yield

-98.21%

IKNA Fundamentals

IKNA Revenue

Revenue (TTM)

9.2M

Rev. Growth (Yr)

-87.92%

Rev. Growth (Qtr)

-44.43%

IKNA Earnings

Earnings (TTM)

-70.1M

Earnings Growth (Yr)

-13.55%

Earnings Growth (Qtr)

17.15%

Breaking Down IKNA Revenue

Last 7 days

-6.2%

Last 30 days

20.3%

Last 90 days

12.2%

Trailing 12 Months

-76.1%

How does IKNA drawdown profile look like?

IKNA Financial Health

Current Ratio

15.85

IKNA Investor Care

Shares Dilution (1Y)

33.05%

Diluted EPS (TTM)

-1.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202317.5M19.2M14.0M9.2M
202230.9M27.7M30.4M15.6M
20219.4M9.9M10.8M31.0M
20200009.2M

Tracking the Latest Insider Buys and Sells of Ikena Oncology, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 04, 2023
bonita david p
acquired
-
-
153,121
-
Aug 04, 2023
orbimed advisors llc
acquired
-
-
153,121
-
Jun 24, 2022
bonita david p
bought
-803,975
4.96281
-162,000
-
Jun 24, 2022
orbimed advisors llc
bought
-803,975
4.96281
-162,000
-
Jun 23, 2022
orbimed advisors llc
bought
-86,884
3.71
-23,419
-
Jun 23, 2022
bonita david p
bought
-86,884
3.71
-23,419
-
Jun 22, 2022
orbimed advisors llc
bought
-237,161
3.55
-66,806
-
Jun 22, 2022
bonita david p
bought
-237,161
3.55
-66,806
-

1–10 of 41

Which funds bought or sold IKNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-53,000
-
-%
May 17, 2024
Artal Group S.A.
sold off
-100
-1,969,000
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-31.01
-5,046
4,991
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-43,482
-
-%
May 15, 2024
BVF INC/IL
unchanged
-
-2,623,040
6,772,210
0.19%
May 15, 2024
ADAR1 Capital Management, LLC
new
-
49,700
49,700
0.01%
May 15, 2024
Blue Owl Capital Holdings LP
added
99.18
1,676,760
5,525,390
1.10%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-42.67
-165,928
116,866
-%
May 15, 2024
Atom Investors LP
new
-
14,420
14,420
-%
May 15, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
unchanged
-
-158,345
408,818
-%

1–10 of 50

Are Funds Buying or Selling IKNA?

Are funds buying IKNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IKNA
No. of Funds

Unveiling Ikena Oncology, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
5.1%
2,469,828
SC 13G/A
Feb 14, 2024
omega fund vi, l.p.
4.7%
2,249,123
SC 13G/A
Feb 14, 2024
citadel advisors llc
0.3%
6
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Oct 19, 2023
gilead sciences, inc.
6.7%
2,931,467
SC 13G
Sep 21, 2023
orbimed advisors llc
5.2%
2,189,111
SC 13D/A
Sep 14, 2023
orbimed advisors llc
5.5%
2,342,232
SC 13D/A
Feb 14, 2023
biotechnology value fund l p
3.8%
1,358,593
SC 13G/A
Feb 14, 2023
citadel advisors llc
5.9%
6
SC 13G/A

Recent SEC filings of Ikena Oncology, Inc.

View All Filings
Date Filed Form Type Document
Jun 10, 2024
8-K
Current Report
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
May 28, 2024
8-K
Current Report
May 13, 2024
10-Q
Quarterly Report

Peers (Alternatives to Ikena Oncology, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.5B
6.8B
-6.49% 10.99%
-8.63
7.52
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.9B
2.0B
5.23% -22.79%
-59.97
9.94
75.20% 68.82%
16.1B
2.5B
9.54% -12.06%
78.3
6.51
13.74% 186.89%
14.0B
3.8B
8.61% 0.73%
18.78
3.72
8.58% 129.81%
MID-CAP
5.0B
107.9M
-7.86% 61.07%
-9.24
48.09
54.84% -28.31%
4.8B
524.1M
-6.67% -54.57%
-11.55
9.2
394.93% 39.61%
3.6B
251.0M
-3.70% -15.05%
-12.06
14.23
73.58% -86.73%
3.0B
240.7M
-5.00% -33.10%
-6.24
12.77
-1.03% -213.92%
2.4B
813.8M
-3.54% -38.85%
-1.4K
2.99
56.43% 98.83%
2.0B
996.6M
-5.63% 89.11%
-4.95
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-8.17% 14.57%
27.53
4.36
60.38% -34.49%
455.3M
881.7K
-5.75% 469.52%
-13.49
481.06
-77.61% 33.36%
209.1M
4.2M
-26.57% 40.10%
-1.67
50.27
-66.30% 48.24%
18.5M
2.1M
-8.15% 218.45%
-0.8
7.61
-13.45% 69.54%

Ikena Oncology, Inc. News

Latest updates
Yahoo Canada Sports19 Jun 202401:41 am
Defense World13 Jun 202404:18 pm
Yahoo Movies Canada12 Jun 202412:35 pm

Ikena Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Revenue-44.4%658,5001,185,0002,004,0005,313,0005,450,0006,402,000382,0003,384,00020,216,5003,746,0003,549,0003,474,00065,0002,829,0003,073,0003,227,000
Operating Expenses9.1%22,567,00020,688,00020,494,00020,828,00020,564,50024,278,00021,333,00020,346,00017,425,00018,268,00016,236,00013,194,00026,117,0009,062,0008,132,00010,403,000
  S&GA Expenses37.4%8,293,0006,034,0005,322,0005,276,0004,925,0005,428,0005,845,0006,003,0005,087,0004,893,0004,862,0003,173,0002,715,0001,844,0001,798,0002,510,000
  R&D Expenses-2.6%14,274,00014,654,00015,172,00015,552,00015,639,50018,850,00015,488,00014,343,00012,338,00013,375,00011,374,00010,021,00023,402,0007,218,0006,334,0007,893,000
EBITDA Margin-51.1%-7.35-4.86-3.54-3.87-4.35-----------
Earnings Before Taxes-----14,219,000------------
EBT Margin-51.3%-7.46-4.93-3.59-3.92-4.40-----------
Net Income-12.4%-19,489,000-17,343,000-17,115,000-14,219,000-14,097,000-17,338,000-20,491,000-16,839,0002,797,000-14,515,000-12,681,000-9,716,000-26,051,000-6,222,000-5,038,000-6,945,000
Net Income Margin-65.4%-7.44-4.50-3.27-3.77-4.40-1.71-1.77-1.33-1.10-5.81-5.51-----
Free Cashflow-10.4%-22,081,000-19,997,000-18,143,000-19,936,000-17,886,000-18,350,000-19,487,000-19,817,000-13,918,000-18,174,000-15,911,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-10.1%173192215172152172190211228248262279294168
  Current Assets-9.8%161179201161141160178199216237252269283166
    Cash Equivalents-55.9%53.0012012171.0029.0061.0067.0048.0047.00233246264281163
  Net PPE-63.0%1.002.003.003.003.003.003.003.002.002.002.002.002.001.00
Liabilities-21.9%17.0022.0028.0015.0017.0025.0032.0037.0035.0040.0058.0063.0066.0063.00
  Current Liabilities-28.4%10.0014.0019.0012.0014.0022.0025.0029.0025.0027.0031.0031.0030.0028.00
Shareholder's Equity-8.5%155170155157135147159174193208203216228-
  Retained Earnings-5.7%-298-282-262-245-228-214-200-182-162-145-148-133-121-111
  Additional Paid-In Capital0.4%45445241840336436236035835635335135034910.00
Shares Outstanding0%48.0048.0044.0042.0036.0036.0036.0036.0036.0036.0025.0036.00--
Float----179-58.00-----297--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations16.1%-18,304-21,819-19,997-18,143-19,784-17,655-17,219-19,451-19,784-13,368-17,990-15,724-13,170-12,570-7,670-7,712-9,874
  Share Based Compensation14.0%2,0011,7551,9981,8792,0001,8591,8111,9551,9001,5811,4491,262885650418354375
Cashflow From Investing-339.2%-48,73820,37631,89422,680-10,80610,49935,78220,486-166,051-550-184-187-8393,038-1.00-117
Cashflow From Financing-100.0%-60.0038,918--1.0024.0057549523669.00-1,095132,528116,163--21.00
  Buy Backs----663-------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IKNA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues [Abstract]  
Collaboration revenue $ 5,313
Operating expenses:  
Research and development$ 9,64515,552
General and administrative5,9995,276
Restructuring and other charges2,582 
Total operating expenses18,22620,828
Loss from operations(18,226)(15,515)
Other income (expense):  
Investment income2,1141,296
Other income (expense)(7) 
Total other income, net2,1071,296
Loss before income taxes(16,119)(14,219)
Income tax expense(27) 
Net loss(16,146)(14,219)
Other comprehensive income (loss):  
Unrealized gain (loss) on marketable securities(265)272
Total comprehensive loss$ (16,411)$ (13,947)
Net loss per share:  
Net loss per share, basic$ (0.33)$ (0.39)
Net loss per share, diluted$ (0.33)$ (0.39)
Weighted-average common shares outstanding, basic48,258,11136,257,493
Weighted-average common shares outstanding, diluted48,258,11136,257,493

IKNA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 52,852$ 119,894
Marketable securities104,49755,571
Prepaid expenses and other current assets3,8173,197
Total current assets161,166178,662
Property and equipment, net8642,335
Right-of-use asset5,2415,686
Deposits and other assets5,5115,409
Total assets172,782192,092
Current liabilities:  
Accounts payable1,9092,066
Accrued expenses and other current liabilities4,8178,581
Operating lease liability3,4433,558
Total current liabilities10,16914,205
Long-term portion of operating lease liability6,3027,180
Other long-term liabilities964950
Total liabilities17,43522,335
Commitments and contingencies (Note 8)
Stockholders equity  
Preferred stock, $0.001 par value - 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; No shares issued and outstanding as of March 31, 2024 or December 31, 2023
Common stock, $0.001 par value, 150,000,000 shares authorized and 48,258,111 shares issued and outstanding at March 31, 2024 and December 31, 20234848
Additional paid-in capital454,143452,142
Accumulated other comprehensive loss(313)(48)
Accumulated deficit(298,531)(282,385)
Total stockholders' equity155,347169,757
Total liabilities and stockholders' equity$ 172,782$ 192,092
IKNA
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEhttps://ikenaoncology.com
 INDUSTRYBiotechnology
 EMPLOYEES59

Ikena Oncology, Inc. Frequently Asked Questions


What is the ticker symbol for Ikena Oncology, Inc.? What does IKNA stand for in stocks?

IKNA is the stock ticker symbol of Ikena Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ikena Oncology, Inc. (IKNA)?

As of Thu Jun 20 2024, market cap of Ikena Oncology, Inc. is 80.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IKNA stock?

You can check IKNA's fair value in chart for subscribers.

What is the fair value of IKNA stock?

You can check IKNA's fair value in chart for subscribers. The fair value of Ikena Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ikena Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IKNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ikena Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether IKNA is over valued or under valued. Whether Ikena Oncology, Inc. is cheap or expensive depends on the assumptions which impact Ikena Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IKNA.

What is Ikena Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 20 2024, IKNA's PE ratio (Price to Earnings) is -1.14 and Price to Sales (PS) ratio is 8.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKNA PE ratio will change depending on the future growth rate expectations of investors.